9 results on '"Bavbek S"'
Search Results
2. Rapid Drug Desensitization with Chemotherapeutics (Platins, Taxanes, and Others): A Single-Center Retrospective Study.
- Author
-
Kendirlinan R, Gümüşburun R, Çerçi P, Özbek E, Altıner S, Çelebi Sözener Z, Soyyiğit Ş, Aydın Ö, and Bavbek S
- Subjects
- Adult, Drug Hypersensitivity diagnosis, Female, Humans, Male, Middle Aged, Retrospective Studies, Skin Tests, Taxoids adverse effects, Treatment Outcome, Antineoplastic Agents adverse effects, Desensitization, Immunologic methods, Drug Hypersensitivity immunology, Drug Hypersensitivity therapy
- Abstract
Background: Rapid drug desensitization (RDD) induces a temporary tolerance to chemotherapeutics that induce hypersensitivity reactions (HSRs)., Purpose: Our objective is to report our experience with RDD to platins, taxanes, etoposide, doxorubicin, and irinotecan., Methods: The study was conducted as a retrospective chart review of patients with symptoms of HSRs to chemotherapeutics. HSRs were classified as grade I, II, or III, based on their severity. Skin prick/intradermal tests were performed with implicated chemotherapeutics. A 12-step RDD protocol was used., Results: The study consisted of 38 women and 3 men (mean age 53.3 ± 11.6 years). Patients had ovarian (n = 13, 31.8%), breast (n = 10, 24.4%), colon (n = 7, 17%), lung (n = 4, 9.8%), and other cancers (n = 7; endometrial sarcoma, testicular cancer, uterine cancer, ampulla of Vater tumor, choledochal tumor, peritonitis carcinomatosa, and Merkel cell carcinoma, n = 1, respectively). Twenty-two patients experienced HSRs to platins, 15 to taxanes, and 4 to other chemotherapeutics (doxorubicin, irinotecan, and etoposide). A total of 122 RDDs (47 to platins, 52 to taxanes, 23 to other chemotherapeutics) were performed. In 25 (61%) patients no reactions occurred during RDD, but breakthrough reactions developed in 16 patients (39%) with platins (n = 11), taxanes (n = 3), doxorubicin (n = 1), and irinotecan (n = 1). RDD procedures could not be completed in only 2 patients with grade II breakthrough reactions to carboplatin and oxaliplatin., Conclusion: In our experience, 98.3% of 122 RDDs were completed. We found that RDD was safe and effective in this the largest series of RDD with chemotherapeutics in our country., (© 2019 S. Karger AG, Basel.)
- Published
- 2019
- Full Text
- View/download PDF
3. Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity.
- Author
-
Cortellini G, Romano A, Santucci A, Barbaud A, Bavbek S, Bignardi D, Blanca M, Bonadonna P, Costantino MT, Laguna JJ, Lombardo C, Losappio LM, Makowska J, Nakonechna A, Quercia O, Pastorello EA, Patella V, Terreehorst I, Testi S, Cernadas JR, Dionicio Elera J, Lippolis D, Voltolini S, and Grosseto D
- Subjects
- Aged, Algorithms, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Aspirin administration & dosage, Clinical Decision-Making, Comorbidity, Drug Hypersensitivity diagnosis, Female, Humans, Male, Middle Aged, Myocardial Ischemia diagnosis, Myocardial Ischemia drug therapy, Treatment Outcome, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Aspirin adverse effects, Desensitization, Immunologic adverse effects, Desensitization, Immunologic methods, Drug Hypersensitivity complications, Drug Hypersensitivity therapy, Myocardial Ischemia complications
- Abstract
Background: Hypersensitivity to acetylsalicylic acid (ASA) constitutes a serious problem for subjects with coronary artery disease. In such subjects, physicians have to choose the more appropriate procedure between challenge and desensitization. As the literature on this issue is sparse, this study aimed to establish in these subjects clinical criteria for eligibility for an ASA challenge and/or desensitization., Methods: Collection and analysis of data on ASA challenges and desensitizations from 10 allergy centers, as well as consensus among the related physicians and an expert panel., Results: Altogether, 310 subjects were assessed; 217 had histories of urticaria/angioedema, 50 of anaphylaxis, 26 of nonimmediate cutaneous eruptions, and 17 of bronchospasm related to ASA/nonsteroidal anti-inflammatory drugs (NSAID) intake. Specifically, 119 subjects had index reactions to ASA doses lower than 300 mg. Of the 310 subjects, 138 had an acute coronary syndrome (ACS), 101 of whom underwent desensitizations, whereas 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges. Overall, 163 subjects underwent challenges and 147 subjects underwent desensitizations; 86 of the latter had index reactions to ASA doses of 300 mg or less. Ten subjects reacted to challenges, seven at doses up to 500 mg, three at a cumulative dose of 110 mg. The desensitization failure rate was 1.4%., Conclusions: In patients with stable CIHD and histories of nonsevere hypersensitivity reactions to ASA/NSAIDs, an ASA challenge is advisable. Patients with an ACS and histories of hypersensitivity reactions to ASA, especially following doses lower than 100 mg, should directly undergo desensitization., (© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
4. Rapid Drug Desensitization with Biologics: A Single-Center Experience with Four Biologics.
- Author
-
Bavbek S, Kendirlinan R, Çerçi P, Altıner S, Soyyiğit Ş, Çelebi Sözener Z, Aydın Ö, and Gümüşburun R
- Subjects
- Adult, Aged, Drug Hypersensitivity diagnosis, Female, Humans, Male, Middle Aged, Retrospective Studies, Skin Tests, Treatment Outcome, Young Adult, Biological Products therapeutic use, Desensitization, Immunologic methods, Drug Hypersensitivity immunology, Drug Hypersensitivity therapy
- Abstract
Background: Rapid drug desensitization (RDD) induces a temporary tolerance to biologics which induce hypersensitivity reactions (HSRs). Data are limited regarding the use of RDD outside the USA. Our purpose was to report our data on RDD to rituximab, infliximab, cetuximab, and trastuzumab., Methods: The study was conducted as a retrospective chart review of patients with symptoms of HSRs to biologics. HSRs were classified as grades I, II, and III, based on their severity. Skin-prick tests/intradermal tests (IDTs) were performed with the implicated biologics. The 12-step RDD protocol was used., Results: The study group comprised 11 women and 6 men (mean age: 47 ± 11.7 years). Fourteen patients experienced HSRs to rituximab; 3 had HSRs to cetuximab, infliximab, and trastuzumab, respectively. HSRs to cetuximab, infliximab, and trastuzumab occurred during the first infusion and were all grade III. Twelve of the 14 patients with rituximab hypersensitivity had a reaction during the first infusion; 10 patients had grade II reactions and 4 had grade III reactions. Respiratory symptoms were the most frequent presentation of HSR. Skin tests with rituximab were performed on 10 patients; only 3 resulted in positive IDTs (with 1:100 dilutions) and the other tests were negative as were those performed with the other biologics. Of 96 RDDs, 89 desensitizations were performed with rituximab, 5 with cetuximab, 1 with infliximab, and 1 with trastuzumab. There were 12 (13.5%) breakthrough reactions, all of which were associated with rituximab and were less severe than the initial reactions., Conclusion: RDD was found to be safe and effective in the largest case series of RDDs with biologics in our country, Turkey., (© 2017 S. Karger AG, Basel.)
- Published
- 2016
- Full Text
- View/download PDF
5. Rapid subcutaneous desensitization for the management of local and systemic hypersensitivity reactions to etanercept and adalimumab in 12 patients.
- Author
-
Bavbek S, Ataman Ş, Akıncı A, and Castells M
- Subjects
- Adult, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology, Female, Humans, Male, Middle Aged, Skin Tests, Adalimumab adverse effects, Antirheumatic Agents adverse effects, Desensitization, Immunologic, Drug Hypersensitivity therapy, Etanercept adverse effects
- Published
- 2015
- Full Text
- View/download PDF
6. Injection site reaction to adalimumab: Positive skin test and successful rapid desensitisation.
- Author
-
Bavbek S, Ataman Ş, Bankova L, and Castells M
- Subjects
- Adalimumab, Adult, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents administration & dosage, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Diphenhydramine therapeutic use, Dose-Response Relationship, Drug, Drug Eruptions diagnosis, Drug Eruptions drug therapy, Drug Eruptions therapy, Famotidine therapeutic use, Female, Humans, Injections, Subcutaneous, Intradermal Tests, Skin Tests, Time Factors, Antibodies, Monoclonal, Humanized adverse effects, Antirheumatic Agents adverse effects, Desensitization, Immunologic methods, Drug Eruptions etiology, Erythema chemically induced, Pruritus chemically induced
- Published
- 2013
- Full Text
- View/download PDF
7. Injection-site reaction to etanercept: role of skin test in the diagnosis of such reaction and successful desensitization.
- Author
-
Bavbek S, Aydın O, Ataman S, Cahill K, and Castells M
- Subjects
- Adult, Drug Hypersensitivity diagnosis, Drug Hypersensitivity etiology, Drug Hypersensitivity therapy, Etanercept, Humans, Immunoglobulin G administration & dosage, Immunoglobulin G immunology, Male, Receptors, Tumor Necrosis Factor administration & dosage, Receptors, Tumor Necrosis Factor immunology, Spondylitis, Ankylosing drug therapy, Spondylitis, Ankylosing immunology, Desensitization, Immunologic, Immunoglobulin G adverse effects, Skin Tests
- Published
- 2011
- Full Text
- View/download PDF
8. EAACI 2010: cutting-edge research in allergic diseases and their underlying mechanisms.
- Author
-
Bavbek S
- Subjects
- Allergy and Immunology, Biomedical Research trends, Clinical Trials as Topic, Contrast Media adverse effects, Drug Hypersensitivity drug therapy, Drug Hypersensitivity epidemiology, Drug Hypersensitivity physiopathology, Europe, Humans, Hypersensitivity etiology, Societies, Scientific, Desensitization, Immunologic, Drug Hypersensitivity immunology, Hypersensitivity immunology
- Abstract
The European Academy of Allergy and Clinical Immunology (EAACI) congress is considered to be one of the most important annual meetings in the allergy field. This year, the EAACI 2010 took place in London, UK, during 5-9 June, and focused on 'cutting-edge research in allergic diseases and their underlying mechanisms'.
- Published
- 2010
- Full Text
- View/download PDF
9. COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals—EAACI recommendations
- Author
-
Jutel M., Torres M.J., Palomares O., Akdis C.A., Eiwegger T., Untersmayr E., Barber D., Zemelka-Wiacek M., Kosowska A., Palmer E., Vieths S., Mahler V., Canonica W.G., Nadeau K., Shamji M.H., Agache I., Akdis M., Khaitov M., Alvarez-Perea A., Alvaro-Lozano M., Atanaskovic-Markovic M., Backer V., Barbaud A., Bavbek S., de Blay F., Bonini M., Bonini S., van Boven J.F.M., Brockow K., Cazzola M., Chatzipetrou A., Chivato T., Cianferoni A., Corren J., Cristoph-Caubet J., Dunn-Galvin A., Ebisawa M., Firinu D., Gawlik R., Gelincik A., del Giacco S., Mortz C.G., Jurgen Hoffmann H., Hoffmann-Sommergruber K., Klimek L., Knol E., Lauerma A., de Llano L.P., Matucci A., Meyer R., Moreira A., Morita H., Patil S.U., Pfaar O., Popescu F.-D., del Pozo V., Price O.J., van Ree R., Fernandez-Rivas M., Rogala B., Romano A., Santos A., Sediva A., Skypala I., Smolinska S., Sokolowska M., Sturm G., Vultaggio A., Walusiak-Skorupa J., Worm M., University of Zurich, Shamji, Mohamed H, Agache, Ioana, Ear, Nose and Throat, Experimental Immunology, AII - Inflammatory diseases, APH - Global Health, APH - Personalized Medicine, Groningen Research Institute for Asthma and COPD (GRIAC), Value, Affordability and Sustainability (VALUE), and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Subjects
DOWN-REGULATION ,COVID-19 Vaccines ,Immunology ,610 Medicine & health ,IMMUNOGENICITY ,10183 Swiss Institute of Allergy and Asthma Research ,VACCINES ,INFECTION ,Hypersensitivity ,Humans ,Immunology and Allergy ,SARS ,2403 Immunology ,Biological Products ,T-CELL RESPONSES ,SARS-CoV-2 ,IMMUNE-RESPONSES ,Vaccination ,AIT ,Allergens ,Immunoglobulin E ,allergy ,Asthma ,mRNA vaccines ,biologicals ,Desensitization, Immunologic ,SAFETY ,2723 Immunology and Allergy ,immunotherapy ,INFLUENZA VACCINATION ,Covid-19 ,SEVERE ASTHMA ,allergen - Abstract
Immune modulation is a key therapeutic approach for allergic diseases, asthma and autoimmunity. It can be achieved in an antigen-specific manner via allergen immunotherapy (AIT) or in an endotype-driven approach using biologicals that target the major pathways of the type 2 (T2) immune response: immunoglobulin (Ig)E, interleukin (IL)-5 and IL-4/IL-13 or non-type 2 response: anti-cytokine antibodies and B-cell depletion via anti-CD20. Coronavirus disease 2019 (COVID-19) vaccination provides an excellent opportunity to tackle the global pandemics and is currently being applied in an accelerated rhythm worldwide. The vaccine exerts its effects through immune modulation, induces and amplifies the response against the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Thus, as there may be a discernible interference between these treatment modalities, recommendations on how they should be applied in sequence are expected. The European Academy of Allergy and Clinical Immunology (EAACI) assembled an expert panel under its Research and Outreach Committee (ROC). This expert panel evaluated the evidence and have formulated recommendations on the administration of COVID-19 vaccine in patients with allergic diseases and asthma receiving AIT or biologicals. The panel also formulated recommendations for COVID-19 vaccine in association with biologicals targeting the type 1 or type 3 immune response. In formulating recommendations, the panel evaluated the mechanisms of COVID-19 infection, of COVID-19 vaccine, of AIT and of biologicals and considered the data published for other anti-infectious vaccines administered concurrently with AIT or biologicals.
- Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.